Is it the Right Time to Hold Charles River Stock in Your Portfolio?

Zacks11-28 20:19

Charles River Laboratories International, Inc. CRL continues to enhance its portfolio through targeted partnerships and acquisitions, poised to drive growth in the upcoming quarters. The company’s RMS...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486131621?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GmVc8.ZtfGjPFG_U83F8fA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e34d884fa2c79bf8b02903b1effd4c0b","is_english":true,"pubTime":"2024-11-28 20:19","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2486131621","market":"us","top_or_hot":-1,"title":"Is it the Right Time to Hold Charles River Stock in Your Portfolio?","media":"Zacks","content":"<div>\n<p>Charles River Laboratories International, Inc. CRL continues to enhance its portfolio through targeted partnerships and acquisitions, poised to drive growth in the upcoming quarters. The company’s RMS...</p>\n\n<a href=\"https://finance.yahoo.com/news/time-hold-charles-river-stock-121900198.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is it the Right Time to Hold Charles River Stock in Your Portfolio?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs it the Right Time to Hold Charles River Stock in Your Portfolio?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-28 20:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/time-hold-charles-river-stock-121900198.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Charles River Laboratories International, Inc. CRL continues to enhance its portfolio through targeted partnerships and acquisitions, poised to drive growth in the upcoming quarters. The company’s RMS...</p>\n\n<a href=\"https://finance.yahoo.com/news/time-hold-charles-river-stock-121900198.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0009355771.USD","symbol_name":"骏利亨德森环球生命科技A Acc","start_time":0,"source_url":"https://finance.yahoo.com/news/time-hold-charles-river-stock-121900198.html","article_id":"2486131621","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GmVc8.ZtfGjPFG_U83F8fA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e34d884fa2c79bf8b02903b1effd4c0b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486131621","pubTimestamp":1732796340,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Charles River Laboratories International, Inc. CRL continues to enhance its portfolio through targeted partnerships and acquisitions, poised to drive growth in the upcoming quarters. The company’s RMS  is witnessing broad-based growth in all geographic regions for small research models. Sound financial health also bodes well for the stock. Meanwhile, volatilities in the biopharma industry remain a challenge for Charles River. Intense rivalry from other industry players adds to the concern.In the past year, this Zacks Rank #3  stock has risen 1.3% compared with the flat growth of the industryand a 32.4% rise of the S&P 500 composite.Operating as a full-service, early-stage contract research organization, Charles River has a market capitalization of $10.11 billion. The company has an earnings yield of 5.13% compared to the industry’s 3.21% yield. CRL surpassed estimates in each of the trailing four quarters, delivering an average earnings surprise of 9.35%.Find the latest EPS estimates a","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","IS":"IronSource Ltd","BK4585":"ETF&股票定投概念","CRL":"查尔斯河","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4139":"生物科技","BSX":"波士顿科学","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","CDMO":"Avid Bioservices, Inc.","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","BK4082":"医疗保健设备","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","HAE":"美国血液技术","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","PEN":"Penumbra Inc","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","BK4198":"医疗保健用品","LU2506951875.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) ACC","BK4588":"碎股","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","BK4581":"高盛持仓","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU2506952170.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) INC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD"},"translate_title":"现在是在您的投资组合中持有查尔斯河股票的合适时机吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEN":1,"IS":1,"CRL":1,"CDMO":1,"BSX":1,"HAE":0.9},"content_text":"Charles River Laboratories International, Inc. CRL continues to enhance its portfolio through targeted partnerships and acquisitions, poised to drive growth in the upcoming quarters. The company’s RMS (Research Models and Services) is witnessing broad-based growth in all geographic regions for small research models. Sound financial health also bodes well for the stock.  Meanwhile, volatilities in the biopharma industry remain a challenge for Charles River. Intense rivalry from other industry players adds to the concern.\nIn the past year, this Zacks Rank #3 (Hold) stock has risen 1.3% compared with the flat growth of the industry and a 32.4% rise of the S&P 500 composite.\nOperating as a full-service, early-stage contract research organization, Charles River has a market capitalization of $10.11 billion. The company has an earnings yield of 5.13% compared to the industry’s 3.21% yield. CRL surpassed estimates in each of the trailing four quarters, delivering an average earnings surprise of 9.35%.\nFind the latest EPS estimates and surprises on Zacks Earnings Calendar.\nLet’s delve deeper.\nUpsides for CRL       \nStrategic Deals Drive Growth: Charles River broadens the scope of its products and services across the drug discovery and early-stage development continuum through focused partnerships and acquisitions. In September 2024, the company advanced its neuroscience research by integrating Insightec’s focused ultrasound technology into its preclinical services.  Charles River also partnered with CEBINA GmbH, Central European Biotech Incubator and Accelerator, to support its DanubeNeuro acceleration program.\nIt also collaborated with the FOXG1 Research Foundation to advance its gene therapy through clinical trials. Under a contract development and manufacturing organization (CDMO) agreement, the company will manufacture Good Manufacturing Practice- (GMP) plasmid DNA for AAVantgarde.\nImage Source: Zacks Investment Research\nRMS Prospects Bright: Over the past several quarters, the company has witnessed strong growth within the insourcing solutions (IS) business led by the CRADL (Charles River Accelerator and Development Labs) initiative. Charles River is consistently expanding CRADL’s footprint organically and through the acquisition of Explora BioLabs, a provider of contract vivarium research services. Throughout this year, revenues for small models continued to increase in all geographies, particularly in China and Europe. The acquisition of Noveprim has positively impacted the segment’s growth, contributing $9.1 million to 2024 third-quarter revenues.\nStable Solvency Structure: Charles River exited the third quarter of 2024 with cash and cash equivalents of $210 million, while short-term debt payable was nil.  This is good news for the company’s solvency position, particularly during the time of worldwide macroeconomic complications. Meanwhile, long-term debt decreased 3.4% from the second quarter to $2.33 billion.\nFactors Weighing on CRL\nMacroeconomic Condition: Charles River is experiencing a cautious spending environment, particularly among its global biopharmaceutical and biotechnology clients within the DSA segment. Industry-wide restructuring programs likely precipitated by the IRA or pending patent expirations have led to tighter budgets and reprioritizing their drug pipeline activities this year. Although revenues for biopharma clients increased in the second quarter, proposal activity and bookings began to decline notably and diverge from biotech clients. In the third quarter, the company’s organic revenues declined 2.7% from the challenging biopharmaceutical demand landscape.\nCompetitive Landscape: Charles River competes in the marketplace based on its therapeutic and scientific expertise in early-stage drug research, quality, reputation, flexibility, responsiveness, pricing, innovation and global capabilities. The company primarily faces a broad range of competitors of different sizes and capabilities in each of its three business segments. This fiercely competitive global market impacts the company’s market capitalization scenario.\nCRL Stock Estimate Trend\nThe Zacks Consensus Estimate for CRL’s earnings has moved up 13 cents to $10.14 in the past 30 days.\nThe Zacks Consensus Estimate for the company’s 2024 revenues is pegged at $4.02 billion, suggesting a 2.7% decrease from the year-ago reported number.\nKey Picks\nSome better-ranked stocks in the broader medical space are Haemonetics HAE, Boston Scientific BSX and Penumbra PEN.\nHaemonetics has an earnings yield of 5.41% compared with the industry’s 1.75%. Haemonetics’ earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed on one occasion, the average surprise being 2.82%. Its shares have risen 8.9% compared with the industry’s 21.2% growth in the past year.\nHAE carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nBoston Scientific, carrying a Zacks Rank #2 at present, has a long-term estimated earnings growth rate of 13.8%. Shares of the company have surged 63.4% compared with the industry’s 23.1% growth. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.29%.\nPenumbra, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 35.3% for 2024 compared with the industry’s 12.8%. Shares of Penumbra have risen 7.8% compared with the industry’s 15.1% growth over the past year. PEN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 10.54%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBoston Scientific Corporation (BSX) : Free Stock Analysis Report\nHaemonetics Corporation (HAE) : Free Stock Analysis Report\nCharles River Laboratories International, Inc. (CRL) : Free Stock Analysis Report\nPenumbra, Inc. (PEN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486131621"}